Drug Profile
Research programme: phosphodiesterase IV inhibitors - Array BioPharma/ICOS
Alternative Names: IC 486051Latest Information Update: 02 Aug 2019
Price :
$50
*
At a glance
- Originator Array BioPharma; ICOS Corporation
- Class
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammation; Major depressive disorder; Overactive bladder
Most Recent Events
- 30 Jul 2019 Array Biopharma has been acquired by Pfizer
- 12 Aug 2011 No development reported - Preclinical for Inflammation in USA (unspecified route)
- 12 Aug 2011 No development reported - Preclinical for Major depressive disorder in USA (unspecified route)